Effects of bezafibrate on HDL2/HDL3 ratio in postmenopausal hypertriglyceridemic women

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 11, Issue 2, 2006, Pages 142-148

  Ushiroyama, Takahisa ^a   Sakuma, Kou ^a   Nosaka, Sakura ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Bezafibrate; High density lipoprotein 2 high density lipoprotein 3; Postmenopausal hypertriglyceridemic women

Indexed keywords

BEZAFIBRATE; ESTROGEN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH DENSITY LIPOPROTEIN 2 HIGH DENSITY LIPOPROTEIN 3 RATIO; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; BEZAFIBRATE; CHOLESTEROL; FEMALE; HUMANS; HYPERLIPOPROTEINEMIAS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, HDL; MIDDLE AGED; POSTMENOPAUSE;

EID: 33748998794     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248406289338     Document Type: Article

References (28)

1. Bengsston C, Lindquist O. Menopausal effects on risk factors for ischaemic heart disease. Maturitas. 1979;1:165-170.
2. Ushiroyama T, Okamoto Y, Sugimoto O. Plasma lipid and lipoprotein levels in perimenopausal women - clinical research in 1198 Japanese women. Acta Obstet Gynecol Scand. 1993; 72:428-433.
3. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. Arterial biology for the investigation of the treatment effects of reducing cholesterol. A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002; 106:2055-2060.
4. Ushiroyama T, Ikeda A, Ueki M. Efficacy and short-term effect of pravastatin, a potent inhibitor of HMG-CoA reductase on hypercholesterolemia in climacteric women. J Med. 1994;25:319-331.
5. Ushiroyama T, Ikeda A, Ueki M. Beneficial effects of pravastatin in peri- and postmenopausal hyperlipidemic women: a 5-year study on serum lipid and sex hormone levels. Maturitas. 2001;37:201-208.
6. The ALLHAT Officers and Coordinators for the ALL-HAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA. 2002;288:2998-3007.
7. Kennel WB. Importance of hypertension as a major risk factor in cardiovascular disease. In: Bosch J, Grozsmann RJ, eds. Hypertension: Physiopathology and Treatment. McGraw Hill, NY; 1999:888-910.
8. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTLLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
9. Ushiroyama T, Ikeda A, Higashiyama T, et al. Effects of bezafibrate on serum lipid concentrations in hypertriglyceridemic perimenopausal patients and on -With effects on serum remnant like particles (RLP-C) metabolism and endocrinologic changes. J Jap Men Soc. 1996;4:240-245.
10. Manninen V, Tenkanen L, Koskinen P. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation. 1992;85:37-45.
11. Assmann G, Schulte H. Relation of high density lipoprotein cholesterol and riglyceride to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733-737.
12. Eisenberg S, Gavish D, Oschry Y, Fainaru M, Deckelbaum RJ. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. J Clin Invest. 1984;74:470-482.
13. Ushiroyama T, Ikeda A, Higashio S, Ueki M. Coagulofibrinolysis assessment of effects of bezafibrate on hypertriglyceridemia in postmenopausal women. Blood Coagul Fibrinolysis. 2000-11: 709-714.
14. Sola R, Baudet MF, Motta C, Maille M, Boisnier C, Jacotot B. Effects of dietary fats on the fluidity of human high-density lipoprotein: influence of the overall composition and phospholipid fatty acids. Biochim Biophys Acta. 1990;1043:43-51.
15. Sola R, Motta C, Maille M, et al. Dietary monounsaturated fatty acids enhance cholesterol efflux from fibroblasts. Relation to fluidity, phospholipid fatty acid composition, overall composition and size of HDL3. Arterioscler Thromb. 1993; 13:958-966.
16. Va Ville AE, Sola R, Balanya J, Turner PR, Masana L. In vitro oxidised HDL is recognized by the scavenger receptor of macrophages: implications for its protective role in vivo. Atherosclerosis. 1994;106:179-189.
17. Panzenboeck U, Balazs Z, Sovic A, et al. ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells. J Biol Chem. 2000;277: 42781-42789.
18. Marcil M, Yu L, Krimbou L, et al. Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency. Arterioscler Thromb Vasc Biol. 1999;19:150-169.
19. La Ville AE, Sola R, Motta C, et al. Physicochemical changes in HDL3 after bezafibrate treatment: influence on free cholesterol efflux from human fibroblasts. Cardiovasc Drugs Ther. 1997;11:653-658.
20. Durrington PN, Mackness MI, Bhatnagar D, et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis. 1998;138:217-225.
21. Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationship of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol. 1998;32:1648-1656.
22. Meco JF, Vila R, Pujol R, et al. Improvement in endothelial dysfunction in patients with hypoalphalipoproteinemia and coronary artery disease treated with bezafibrate. J Cardiovas Pharmacol. 2001;38:250-258.
23. Ushiroyama T, Ikeda A, Sakai M, et al. Effects of unkeito, an herbal medicine, on endocrine function and ovulation in women with high basal levels of luteinizing hormone secretion. J Reprod Med. 2001;46:451-456.
24. Oram JF. Effects of high density lipoprotein subfractions on cholesterol homeostasis in human fibroblasts and arterial smooth muscle cells. Arteriosclerosis. 1983;3:420-432.
25. Ushiroyama T, Sakuma K, Ikeda A, et al. Evaluation of serum HDL2/HDL3 ratio in lipid metabolism in postmenopausal women. Bull Osaka Med Coll. 2005;51:9-15.
26. Fielding PE, Kawano M, Catapano AL, et al. Unique epitope of apo A-I expression in pre-beta-high density lipoprotein and its role in the catalyzed efflux of cellular cholesterol. Biochemistry. 1994;33:6981-6985.
27. Homma Y, Ozawa JF, Kobayashi T, et al. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin: cholesterol acetyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atheloscrelosis. 1994; 106:191-201.
28. Ushiroyama T, Sakuma K, Ikeda A, et al. The HDL2/HDL3 ratio in menopause. Int J Gynecol Obstet. 2005;88:303-308.